Académique Documents
Professionnel Documents
Culture Documents
American Joint Committee on Cancer. American Joint Committee on Cancer. Cancer Staging: What You Need to Know?
Chicago, IL: American Joint Committee on Cancer; 2010.
T4 Prostate Cancer –
regional/distant spread
90
• 19% Maori 80
70
diagnosed with
60
metastatic 50
disease 40
30
• 10% of NZ 20
Europeans 10
0
40-59 60-69 70-79 80+
Local Local spread Mets
Outcomes from prostate cancer
Outcomes from prostate cancer
= UK survival
Outcomes for Māori – all cases and
non localised cases
71.8%
(664/925)
22.1% (266/1205)
31.2% (4978/15947)
Lawrenson, et al. J Cancer. 2014; 5(3): 214–220. Published online Feb 14, 2014. doi: 10.7150/jca.8152
Māori compared with non-Māori
• Māori men with metastatic disease were more
likely to receive anti-androgen treatment (72.5%)
compared with non Māori (58.2%)
• Māori men were more likely to be treated with
orchidectomy (3.2%) compared to non Māori
(2.2%)
Study Two
Method
• Identified 2127 patients diagnosed with prostate
cancer in the Midland Cancer Network region from the
NZ Cancer Registry (2009-2012)
• Clinical notes reviewed and all patients staged
• Linked the patient records of those staged as
metastatic to the Pharmaceutical and Mortality
national data sets
• Costing data from National Hospital data and Waikato
District Health Board costing data
Distribution of sample by age and
ethnicity: 234 men (11.0%) metastatic
100
90
80
70
60
50
40
30
20
10
0
40-59 60-69 70-79 80+
Non Māori Māori
Outcomes for Māori and non Māori with metastatic prostate
cancer (n=234)
Maori
Characteristics of patients treated
Number of
Radiotherapy ADT Chemotherapy
patients
Ethnicity
Cyproterone Goserelin
Bicalutamide Flutamide Leuprorelin
acetate acetate